Transgene Announces the Recruitment of Dr. Nathalie Adda as Chief Medical Officer
Strengthens management team ahead of upcoming pivotal trials
Strasbourg, France, September 20, 2012 - Transgene S.A. (Euronext Paris: FR0005175080) today announces the recruitment of Dr. Nathalie Adda as Chief Medical Officer ("CMO"). Responsible for medical and regulatory affairs of the Company, Dr. Adda will be a member of its executive committee.
Nathalie Adda is a Medical Doctor and a graduate of the Faculty of Medicine of the University of Paris VII where she specialized in infectious diseases. She also has a Master degree in bio-statistics. She has more than 15-year experience in the pharmaceutical industry, in the United States, working in the clinical development of products from early phase to market launch.
Since 2006, Dr. Nathalie Adda held the position of Senior Medical Director at Vertex Pharmaceuticals in Cambridge, MA, USA, where she was responsible for the clinical development of Telaprevir, a drug approved in 2011, in the USA and Europe, for the treatment of chronic hepatitis C.
Before her time at Vertex, Dr. Nathalie Adda held similiar roles as Associate Director, Clinical Development at Gilead, as well as at Triangle Pharmaceuticals and Boehringer Ingelheim.
Dr. Nathalie Adda will be based in Cambridge, Massachusetts, USA.
Dr. Jean-Marc Limacher, Director, Clinical Development and Catherine Mathis, Director, Regulatory Affairs, will report to Dr. Nathalie Adda.
"The addition of Nathalie Adda and the experience she brings represent a valuable asset for Transgene as the Company enters the early planning for its pivotal studies" stated Philippe Archinard, Chairman and CEO of Transgene. He added: "Her recruitment comes in the context of the strengthening of our executive committee and follows the 2010 arrivals of both Patrick Mahieux as Vice President, Industrial and Pharmaceutical Operations and Stéphane Boissel as Executive Vice President and CFO. These organizational changes are in line with the stage of maturity of Transgene and confirm its international development."
Transgene, a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases and has four compounds in phase 2 clinical development: TG4010 and JX594/TG6006 having already completed initial phase 2 trials, TG4001 and TG4040. Transgene has concluded strategic agreements for the development of two of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers and an in-licensing agreement with US-based Jennerex, Inc. to develop and market JX594/TG6006, an oncolytic virus. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at www.transgene.fr.
This press release contains forward-looking statements referring to possible upcoming registration trials of the Company's products. The Company's anticipated planning to start such trials is based on current advancement stage and data estate generated with the Company's products, but may vary based on future pre-clinical or clinical data the Company anticipates to generate in 2012 and 2013 with its products. For further information on the risks and uncertainties involved in the testing and development of Transgene's product candidates, see Trangene's Document de Référence on file with the French Autorité des marchés financiers on its website at http://www.amffrance.org and on Transgene's website at www.transgene.fr .
Philippe Archinard, Chairman & CEO, +33 (0)3 88 27 91 22
Stéphane Boissel, Executive Vice President & CFO, +33 (0)3 88 27 91 02
Elisabetta Castelli, Director IR, +33 (0)1 44 08 55 05
Raimund Gabriel, +49 89 210 228 30
Shaun Brown, +44 207 148 5998
|TRANSGENE||Euronext Paris||3.19 (c)||-1.85%||98 485|